Newsroom | 23356 results

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe. The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It comp...

VENLO, Niederlande & HILDEN, Deutschland--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Markteinführung des CE-IVDR-zertifizierten QIAstat-Dx BCID GN Plus AMR Panels bekannt gegeben. Damit bietet die QIAstat-Dx-Plattform in Europa nun ein umfassendes Angebot für die Diagnostik von Blutstrominfektionen. Das neue QIAstat-Dx BCID GN Plus AMR Panel weist 13 gramnegative bakterielle Zielpathogene und 18 Marker für antimikrobielle Resistenzen (AMR) aus positiv...

CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Health Canada has granted a license for its Alethia® CMV assay. The addition of CMV expands Meridian's existing Alethia menu, which includes C. difficile, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis assays. This clearance expands Meridian's molecular diagnostic offerings in the Canadian market. The Alethia pla...

ACCRA, Ghana--(BUSINESS WIRE)--Revna Biosciences, Ghana's first precision medicine company, is contributing to transforming the landscape of healthcare in Ghana by offering advanced molecular tests for oncology, infectious diseases, etc. locally. Tests that were previously only available overseas due to technological constraints, often taking weeks to return results, are now accessible within the country and completed in a matter of days. This strategic move has reduced turnaround time for test...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (« MindWalk » ou la « Société ») (NASDAQ : HYFT), une entreprise spécialisée dans l’IA bio-native, a annoncé aujourd’hui qu’elle publierait ses résultats financiers pour le quatrième trimestre et l’ensemble de l’exercice 2026, et qu’elle tiendrait une conférence téléphonique le mercredi 22 juillet 2026, à 17 h, heure de l’Est. Les résultats financiers seront publiés dans un communiqué de presse avant la conférence téléphonique, qui compren...

ATLANTA--(BUSINESS WIRE)--Italian IVD leader DIESSE Diagnostica Senese establishes DIESSE Inc., its first direct U.S. subsidiary, based in Atlanta...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: HYFT), a Bio-Native AI company, today announced that it will report financial results for the fourth quarter and full fiscal year 2026 and host a conference call on Wednesday, July 22, 2026, at 5:00 p.m. Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session. Conference Call and Webcast...

DOVER, Del.--(BUSINESS WIRE)--Precisio announced the continuation of its expanded access program, with dosing of a staph lysin called ClyO (LYSG101) to a patient with chronic prosthetic joint infection. Under an FDA-approved expanded-access IND, administration of ClyO was initiated on June 1. The treatment follows a 4 month protocol with a minimum 6 month follow-up. Outcomes to be tracked include safety, improvements of clinical signs and symptoms, and either durable eradication or sustained sup...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan...

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2026 results on Tuesday, July 28, 2026, after the close of the market. Acadia will host a conference call with institutional investors and analysts on Wednesday, July 29, 2026 at 9:00 a.m. ET. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website, and the archived webcast will be availabl...